APA (7th ed.) Citation

Senagolage, M. D., Blaylock, H. Z., Khan, S., Skuli, S. J., Carroll, M. P., & McNerney, M. E. NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation. Elsevier.

Chicago Style (17th ed.) Citation

Senagolage, Madhavi D., Hunter Z. Blaylock, Saira Khan, Sarah J. Skuli, Martin P. Carroll, and Megan E. McNerney. NAMPT Haploinsufficiency Is a Collateral Lethal Therapeutic Vulnerability in High-risk Myeloid Malignancies with TP53 Inactivation. Elsevier.

MLA (9th ed.) Citation

Senagolage, Madhavi D., et al. NAMPT Haploinsufficiency Is a Collateral Lethal Therapeutic Vulnerability in High-risk Myeloid Malignancies with TP53 Inactivation. Elsevier.